Voacamine: Alkaloid with its essential dimeric units to reverse tumor multidrug resistance.


Journal

Toxicology in vitro : an international journal published in association with BIBRA
ISSN: 1879-3177
Titre abrégé: Toxicol In Vitro
Pays: England
ID NLM: 8712158

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 09 10 2019
revised: 13 02 2020
accepted: 01 03 2020
pubmed: 7 3 2020
medline: 23 12 2020
entrez: 6 3 2020
Statut: ppublish

Résumé

Search for natural substances in association with conventional chemotherapeutic drugs with a chemiosensitizing action easily accessible to the tumor mass has encouraged our studies on voacamine (VOA) and its monomeric units, voacangine and vobasine. Our previous results showed that VOA sensitized multidrug resistant (MDR) osteosarcoma cells (U-2 OS/DX) to doxorubicin (DOX) cytotoxicity. VOA, extracted by Peschiera fuchsiaefolia plant, is a bisindole alkaloid consisting of an Iboga skeleton (voacangine) directly linked to a 2-acyl indole unit (vobasine). High-performance thin-layer chromatography densitometry demonstrated the purity of VOA, voacangine and vobasine samples. Flow cytometry analysis showed that VOA, voacangine and vobasine enhanced DOX accumulation of U-2 OS/DX cells, in equally way, whereas VOA reduced more efficiently DOX efflux. Optical microscopy and clonogenic assay confirmed that VOA was more effective than voacangine and vobasine in enhancing DOX cytotoxic effect. These results showed that monomers linked together are necessary to modulate resistant phenotype of osteosarcoma cells. To complete the study, we evaluated the effect of three compounds on microtubules by confocal microscopy, suggesting that only the whole molecule depolymerizes the microtubules blocking so DOX efflux-mediated by vesicles.

Identifiants

pubmed: 32135239
pii: S0887-2333(19)30772-6
doi: 10.1016/j.tiv.2020.104819
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
voacamine 2Z504YT5AG
Ibogaine 3S814I130U
Doxorubicin 80168379AG

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104819

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that there are no conflicts of interest.

Auteurs

Maria Condello (M)

National Center for Drug Research and Evaluation, National Institute of Health, Rome 00161, Italy.

Evelin Pellegrini (E)

National Center for Drug Research and Evaluation, National Institute of Health, Rome 00161, Italy.

Giuseppina Multari (G)

National Center for Drug Research and Evaluation, National Institute of Health, Rome 00161, Italy.

Francesca Romana Gallo (FR)

National Center for Drug Research and Evaluation, National Institute of Health, Rome 00161, Italy.

Stefania Meschini (S)

National Center for Drug Research and Evaluation, National Institute of Health, Rome 00161, Italy. Electronic address: stefania.meschini@iss.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH